Linden Thomas Advisory Services LLC Grows Stock Position in Stryker Co. (NYSE:SYK)

Linden Thomas Advisory Services LLC lifted its holdings in Stryker Co. (NYSE:SYK) by 13.6% during the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 3,310 shares of the medical technology company’s stock after purchasing an additional 395 shares during the period. Linden Thomas Advisory Services LLC’s holdings in Stryker were worth $991,000 at the end of the most recent reporting period.

Other large investors also recently added to or reduced their stakes in the company. Farmers & Merchants Trust Co of Chambersburg PA boosted its stake in shares of Stryker by 203.3% during the 4th quarter. Farmers & Merchants Trust Co of Chambersburg PA now owns 91 shares of the medical technology company’s stock worth $27,000 after acquiring an additional 61 shares during the last quarter. HBC Financial Services PLLC bought a new stake in Stryker during the fourth quarter valued at about $37,000. Bourgeon Capital Management LLC purchased a new stake in Stryker in the fourth quarter worth about $37,000. Operose Advisors LLC raised its stake in shares of Stryker by 308.6% in the third quarter. Operose Advisors LLC now owns 143 shares of the medical technology company’s stock worth $39,000 after buying an additional 108 shares during the period. Finally, Venturi Wealth Management LLC lifted its position in shares of Stryker by 97.1% during the 4th quarter. Venturi Wealth Management LLC now owns 136 shares of the medical technology company’s stock valued at $41,000 after buying an additional 67 shares in the last quarter. 77.09% of the stock is currently owned by institutional investors.

Stryker Stock Performance

Stryker stock opened at $336.85 on Thursday. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.58 and a quick ratio of 0.97. The firm has a market capitalization of $128.16 billion, a P/E ratio of 40.83, a price-to-earnings-growth ratio of 2.70 and a beta of 0.89. Stryker Co. has a 1-year low of $249.98 and a 1-year high of $361.41. The company’s 50-day moving average is $349.39 and its 200 day moving average is $314.24.

Stryker (NYSE:SYK) last released its earnings results on Tuesday, January 30th. The medical technology company reported $3.46 EPS for the quarter, beating analysts’ consensus estimates of $3.27 by $0.19. Stryker had a return on equity of 22.99% and a net margin of 15.44%. The firm had revenue of $5.82 billion for the quarter, compared to analysts’ expectations of $5.60 billion. During the same quarter in the prior year, the firm posted $3.00 earnings per share. The company’s quarterly revenue was up 11.8% on a year-over-year basis. Research analysts forecast that Stryker Co. will post 11.86 EPS for the current year.

Stryker Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, April 30th. Stockholders of record on Friday, March 29th will be paid a dividend of $0.80 per share. This represents a $3.20 dividend on an annualized basis and a dividend yield of 0.95%. The ex-dividend date is Wednesday, March 27th. Stryker’s dividend payout ratio is currently 38.79%.

Analysts Set New Price Targets

A number of equities research analysts have commented on SYK shares. Canaccord Genuity Group upgraded shares of Stryker from a “hold” rating to a “buy” rating and set a $360.00 target price on the stock in a research note on Wednesday, January 31st. Truist Financial upped their target price on shares of Stryker from $330.00 to $345.00 and gave the stock a “hold” rating in a report on Wednesday, January 31st. StockNews.com raised Stryker from a “hold” rating to a “buy” rating in a report on Tuesday, January 23rd. Citigroup upped their price objective on Stryker from $362.00 to $406.00 and gave the stock a “buy” rating in a research note on Wednesday, April 3rd. Finally, Roth Mkm lifted their price target on shares of Stryker from $345.00 to $348.00 and gave the company a “buy” rating in a report on Wednesday, January 31st. Three equities research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $340.67.

Insider Transactions at Stryker

In other Stryker news, CAO William E. Berry, Jr. sold 7,690 shares of the business’s stock in a transaction dated Thursday, March 7th. The shares were sold at an average price of $358.48, for a total value of $2,756,711.20. Following the completion of the sale, the chief accounting officer now directly owns 3,675 shares of the company’s stock, valued at approximately $1,317,414. The transaction was disclosed in a filing with the SEC, which is available through this link. In other Stryker news, CAO William E. Berry, Jr. sold 7,690 shares of the firm’s stock in a transaction on Thursday, March 7th. The stock was sold at an average price of $358.48, for a total transaction of $2,756,711.20. Following the transaction, the chief accounting officer now directly owns 3,675 shares in the company, valued at approximately $1,317,414. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Ronda E. Stryker sold 201,146 shares of Stryker stock in a transaction on Monday, February 5th. The shares were sold at an average price of $342.90, for a total value of $68,972,963.40. Following the sale, the director now directly owns 3,755,128 shares of the company’s stock, valued at $1,287,633,391.20. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 212,109 shares of company stock worth $72,845,768. Insiders own 5.90% of the company’s stock.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.